DailyUpdates by e-mail - the publication tracker for the drug discovery community
Oncology Channel - sample 30th March 2004
 If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by Licensing Op. describe data relevant to licensing opportunities. The report icon,  , links through to full analyses relating to pharmaceutical/market developments relating to this work |
Today's top news stories Cell Genesys Reports Synergistic Antitumor Activity for GVAX(R) Cancer Vaccine Plus Docetaxel Chemotherapy in Preclinical Studies EntreMed's Immunomodulator Induces Long-Term Anti-Tumor Activity in Preclinical Models Aegera Initiates Phase 1 Oncology Clinical Trial of XIAP Antisense Designed to Stimulate Apoptotic Cell Death in Cancer Cells CombinatoRx Presents Dual Action Anti-Cancer Drug at AACR Conference Peregrine's VTA & Docetaxel Combination Therapy Inhibits Human Breast Cancer Growth by 93% in Pre-Clinical Studies Exelixis Describes the Discovery of Novel Cancer Targets at AACR Array BioPharma Release: Investigational MEK Inhibitor, ARRY-142886 (AZD6244), Combats Cancer Growth NeoPharm Announces New Approach For Combination Therapy By Entrapping Two Drugs In Single Liposome Using NeoLipid Technology Oxigene shares up as cancer drug effective in mice All of today's news stories updated every 30 minutes Submit your press release or have LeadDiscovery produce a release for you PharmaReports Click here for our full list of PharmaReports Submit your publication to DailyUpdates Subscription to targeted DailyUpdates channels
|
|
Recent journal articles featuring Licensing/Collaborative opportunities Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. Int J Cancer. 2004 May 1;109(5):685-90. Most recent journal article entries Synthesis and biological activity of selective azasugar-based TACE inhibitors. Bioorg Med Chem Lett. 2004 Mar 22;14(6):1569-72. Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1049-52. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther. 2004 Mar 12 [Epub ahead of print]. Novel Gemini analogs of 1alpha,25-dihydroxyvitamin D(3) with enhanced transcriptional activity. Biochem Pharmacol. 2004 Apr 1;67(7):1327-36. Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles. Bioorg Med Chem Lett. 2004 Mar 22;14(6):1411-6 Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR. Bioorg Med Chem Lett. 2004 Feb 23;14(4):909-12. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol. 2004 Apr;24(4):893-900. Selected analyses of pharmaceutical/market development relating to today's selected publications (click on title or the
Previous entries Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res. 2004 Mar 1;10(5):1580-7. Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case. Anticancer Res. 2004 Jan-Feb;24(1):317-9. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res. 2004 Mar 1;10(5):1843-52.
|
